GroPep completes final milestone of the path malaria vaccine initiative

December 19, 2005

Adelaide biotechnology company GroPep has completed the manufacture of two vaccine antigens as part of the project funded by the international PATH Malaria Vaccine Initiative (MVI).

GroPep will supply these vaccine antigens to the MVI for formulation and subsequent use in human clinical trials - expected to start in 2007.

Listed biopharmaceutical company GroPep Limited (ASX :GRO) announced today that it had successfully completed the second and final milestone of its agreement with the PATH Malaria Vaccine Initiative to manufacture malaria vaccine candidates for testing in human clinical trials.

GroPep reported the successful completion to Milestone 1 of the vaccine project in September 2003, developing scalable manufacturing processes for two malaria vaccine candidates.

Milestone 2 required scale-up of production and manufacturing to appropriate quality standards to enable the potential malaria vaccines to be tested in human safety trials. A sufficient quantity of each vaccine antigen has been manufactured.

PATH is an international, non-profit organisation that creates sustainable, culturally relevant solutions allowing global communities to break long-standing cycles of poor health. The Malaria Vaccine Initiative's (MVI) mission is to accelerate the development of malarial vaccines for the developing world. Malaria kills 7000 people each week and there is no vaccine.

MVI Director, Dr Melinda Moree congratulated GroPep on completing this important project milestone. "GroPep has made an important contribution to the quest to develop a vaccine against malaria."

GroPep's CEO, Bob Finder said that the manufacturing project had provided GroPep with a number of technical challenges that had been successfully met.

"As a Company, we are pleased to have successfully completed our part of the project, which may ultimately reduce the impact of this disease on millions of people worldwide," he said.
-end-
About GroPep
GroPep is a world leader in the development, manufacture and commercialisation of biologically active proteins for cell culture and biomedical research. The Company has an active biopharmaceutical development program that establishes proof of concept for products in humans and partners the later stages of product development and marketing with major pharmaceutical companies. GroPep is listed on the Australian Stock Exchange Limited (ASX code: GRO).

Further Information: Mr Tony Mitchell
Chief Financial Officer/Investor Relations Ph: +61 8 8354 7700
investorrelations@gropep.com.au

Research Australia

Related Malaria Articles from Brightsurf:

Clocking in with malaria parasites
Discovery of a malaria parasite's internal clock could lead to new treatment strategies.

Breakthrough in malaria research
An international scientific consortium led by the cell biologists Volker Heussler from the University of Bern and Oliver Billker from the UmeƄ University in Sweden has for the first time systematically investigated the genome of the malaria parasite Plasmodium throughout its life cycle in a large-scale experiment.

Scientists close in on malaria vaccine
Scientists have taken another big step forward towards developing a vaccine that's effective against the most severe forms of malaria.

New tool in fight against malaria
Modifying a class of molecules originally developed to treat the skin disease psoriasis could lead to a new malaria drug that is effective against malaria parasites resistant to currently available drugs.

Malaria expert warns of need for malaria drug to treat severe cases in US
The US each year sees more than 1,500 cases of malaria, and currently there is limited access to an intravenously administered (IV) drug needed for the more serious cases.

Monkey malaria breakthrough offers cure for relapsing malaria
A breakthrough in monkey malaria research by two University of Otago scientists could help scientists diagnose and treat a relapsing form of human malaria.

Getting to zero malaria cases in zanzibar
New research led by the Johns Hopkins Center for Communication Programs, Ifakara Health Institute and the Zanzibar Malaria Elimination Program suggests that a better understanding of human behavior at night -- when malaria mosquitoes are biting -- could be key to preventing lingering cases.

Widely used malaria treatment to prevent malaria in pregnant women
A global team of researchers, led by a research team at the Liverpool School of Tropical Medicine (LSTM), are calling for a review of drug-based strategies used to prevent malaria infections in pregnant women, in areas where there is widespread resistance to existing antimalarial medicines.

Protection against Malaria: A matter of balance
A balanced production of pro and anti-inflammatory cytokines at two years of age protects against clinical malaria in early childhood, according to a study led by ISGlobal, an institution supported by ''la Caixa'' Foundation.

The math of malaria
A new mathematical model for malaria shows how competition between parasite strains within a human host reduces the odds of drug resistance developing in a high-transmission setting.

Read More: Malaria News and Malaria Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.